• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Priority FDA Review of Zilganersen and Tryngolza Pricing Shift Ionis Pharmaceuticals' (IONS) Narrative

    Simply Wall St·04/05/2026 22:18:50
    Listen to the news
    • Ionis Pharmaceuticals recently announced that the FDA accepted for Priority Review its New Drug Application for zilganersen, an RNA-targeted therapy for Alexander disease, with a Prescription Drug User Fee Act target action date set for September 22, 2026, following pivotal data showing clinically meaningful stabilization of gait and favorable safety.
    • An interesting angle for investors is that zilganersen carries multiple expedited and rare-disease designations, highlighting regulatory recognition of its potential impact in a small but severely affected patient population.
    • Next, we’ll examine how the new US$40,000 Tryngolza pricing and positive analyst reaction may reshape Ionis’ investment narrative.

    Uncover the next big thing with 33 elite penny stocks that balance risk and reward.

    Ionis Pharmaceuticals Investment Narrative Recap

    To hold Ionis, you need to believe its RNA platform can convert late stage assets like Olezarsen, DAWNZERA and now zilganersen into durable, profitable franchises despite high development and pricing risk. The zilganersen Priority Review strengthens the case that Ionis can win in rare neurological disease, but it does not change that the near term stock driver and key risk center on US regulatory decisions and pricing outcomes for Olezarsen in severe hypertriglyceridemia.

    The most directly related development is Ionis’ US$40,000 wholesale acquisition cost for Tryngolza in severe hypertriglyceridemia, which surprised the market by coming in above prior guidance while undercutting competitors. This pricing decision sits at the heart of concerns about future revenue compression, payer pushback and margin pressure as Ionis moves from ultra rare FCS into broader patient populations, and it will likely frame how investors interpret the upside from a potential zilganersen launch.

    Yet against this promising clinical and pricing progress, one important risk investors should be aware of is that...

    Read the full narrative on Ionis Pharmaceuticals (it's free!)

    Ionis Pharmaceuticals' narrative projects $1.8 billion revenue and $18.8 million earnings by 2029.

    Uncover how Ionis Pharmaceuticals' forecasts yield a $93.90 fair value, a 26% upside to its current price.

    Exploring Other Perspectives

    IONS 1-Year Stock Price Chart
    IONS 1-Year Stock Price Chart

    Ionis’ recent zilganersen and Tryngolza updates arrive as the most cautious analysts were assuming only about 3% annual revenue growth and no profitability within three years, so if you worry about pricing pressure and narrow indications you may see their more pessimistic view as a useful counterweight and a reminder that reasonable people can look at the same company and reach very different conclusions.

    Explore 3 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth 16% less than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Interested In Other Possibilities?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.